{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:08:19Z","timestamp":1790136499297,"version":"4.0.1"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T00:00:00Z","timestamp":1589414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T00:00:00Z","timestamp":1589414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00223-020-00695-2","type":"journal-article","created":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T08:03:00Z","timestamp":1589443380000},"page":"91-103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Congenital Conditions of Hypophosphatemia Expressed in Adults"],"prefix":"10.1007","volume":"108","author":[{"given":"Gemma","family":"Marcucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,14]]},"reference":[{"key":"695_CR1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40618-014-0202-6","volume":"38","author":"G Marcucci","year":"2015","unstructured":"Marcucci G, Cianferotti L, Beck-Peccoz P, Capezzone M, Cetani F, Colao A, Dav\u00ec MV, degli Uberti E, Del Prato S, Elisei R, Faggiano A, Ferone D, Foresta C, Fugazzola L, Ghigo E, Giacchetti G, Giorgino F, Lenzi A, Malandrino P, Mannelli M, Marcocci C, Masi L, Pacini F, Opocher G, Radicioni A, Tonacchera M, Vigneri R, Zatell MC, Brandi ML (2015) Rare diseases in clinical endocrinology: a taxonomic classification system. J Endocrinol Invest 38:193\u2013259","journal-title":"J Endocrinol Invest"},{"key":"695_CR2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1177\/0004563214521399","volume":"51","author":"P Manghat","year":"2014","unstructured":"Manghat P, Sodi R, Swaminathan R (2014) Phosphate homeostasis and disorders. Ann Clin Biochem 51:631\u2013656","journal-title":"Ann Clin Biochem"},{"key":"695_CR3","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1007\/s00198-018-4618-2","volume":"29","author":"G Marcucci","year":"2018","unstructured":"Marcucci G, Masi L, Ferrar\u00ec S, Haffner D, Javaid MK, Kamenick\u00fd P, Reginster JY, Rizzoli R, Brandi ML (2018) Phosphate wasting disorders in adults. Osteoporos Int 29:2369\u20132387","journal-title":"Osteoporos Int"},{"key":"695_CR4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00774-018-0957-5","volume":"37","author":"MJ McKenna","year":"2019","unstructured":"McKenna MJ, Martin-Grace J, Crowley R, Twomey PJ, Kilbane MT (2019) Congenital hypophosphataemia in adults: determinants of bone turnover markers and amelioration of renal phosphate wasting following total parathyroidectomy. J Bone Miner Metab 37:685\u2013693","journal-title":"J Bone Miner Metab"},{"key":"695_CR5","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1007\/s00467-012-2175-z","volume":"27","author":"M Penido","year":"2012","unstructured":"Penido M, Alon US (2012) Phosphate homeostasis and its role in bone health. Pediatr Nephrol 27:2039\u20132048","journal-title":"Pediatr Nephrol"},{"key":"695_CR6","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrendo.2011.218","volume":"8","author":"LD Quarles","year":"2012","unstructured":"Quarles LD (2012) Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol 8:276\u2013286","journal-title":"Nat Rev Endocrinol"},{"key":"695_CR7","doi-asserted-by":"publisher","first-page":"F282","DOI":"10.1152\/ajprenal.90742.2008","volume":"297","author":"J Gattineni","year":"2009","unstructured":"Gattineni J, Bates C, Twombley K, Dwarakanath V, Robinson ML, Goetz R, Mohammadi M, Baum M (2009) FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Ren Physiol 297:F282\u2013F291","journal-title":"Am J Physiol Ren Physiol"},{"key":"695_CR8","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1210\/jc.2011-1319","volume":"97","author":"EA Imel","year":"2012","unstructured":"Imel EA, Econs MJ (2012) Approach to the hypophosphatemic patient. J Clin Endocrinol Metab 97:696\u2013706","journal-title":"J Clin Endocrinol Metab"},{"key":"695_CR9","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/jcph.570","volume":"56","author":"X Zhang","year":"2016","unstructured":"Zhang X, Imel EA, Ruppe MD et al (2016) Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia. J Clin Pharmacol 56:176\u2013185","journal-title":"J Clin Pharmacol"},{"key":"695_CR10","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.3544","volume":"33","author":"M Collins","year":"2018","unstructured":"Collins M (2018) Burosumab: at long last, an effective treatmen for FGF23-associated hypophosphatemia. J Bone Miner Res 33:1381\u20131382","journal-title":"J Bone Miner Res"},{"key":"695_CR11","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1172\/JCI72829","volume":"124","author":"TO Carpenter","year":"2014","unstructured":"Carpenter TO, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Wooddell MM, Kawakami T, Ito T, Zhang X, Humphrey J, Insogna KL, Peacock M (2014) Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Investig 124:1587\u20131597","journal-title":"J Clin Investig"},{"key":"695_CR12","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1210\/jc.2015-1551","volume":"100","author":"EA Imeal","year":"2015","unstructured":"Imeal EA, Zhang X, Ruppe MD, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey JS, Glorieux FH, Portale AA, Insogna K, Peacock M, Carpenter TO (2015) Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23. J Clin Endocrinol Metab 100:2565\u20132573","journal-title":"J Clin Endocrinol Metab"},{"key":"695_CR13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.bonr.2016.05.004","volume":"5","author":"MD Ruppe","year":"2016","unstructured":"Ruppe MD, Zhang X, Imel EA, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey JS, Glorieux FH, Portale AA, Insogna K, Peacock M, Carpenter TO (2016) Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia. Bone Rep 5:158\u2013162","journal-title":"Bone Rep"},{"key":"695_CR14","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","volume":"33","author":"KL Insogna","year":"2018","unstructured":"Insogna KL, Briot K, Imel EA, Kamenick\u00fd P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, Jan de Beur S, Imanishi Y, Ito N, Lachmann RH, Tanaka H, Perwad F, Zhang L, Chen CY, Theodore-Oklota C, Mealiffe M, San Martin J, Carpenter TO (2018) A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res 33:1383\u20131393","journal-title":"J Bone Miner Res"},{"key":"695_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s11154-008-9075-3","volume":"9","author":"M Bastepe","year":"2008","unstructured":"Bastepe M, Juppner H (2008) Inherited hypophosphatemic disorders in children and the evolving mechanisms of phosphate regulation. Rev Endocr Metab Disord 9:171\u2013180","journal-title":"Rev Endocr Metab Disord"},{"key":"695_CR16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1530\/EJE-08-0818","volume":"160","author":"SS Beck-Nielsen","year":"2009","unstructured":"Beck-Nielsen SS, Brock-Jacobsen B, Gram J, Brixen K, Jensen TK (2009) Incidence and prevalence of nutritional and hereditary rickets in southern Denmark. Eur J Endocrinol 160:491\u2013497","journal-title":"Eur J Endocrinol"},{"key":"695_CR17","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","volume":"62","author":"I Endo","year":"2015","unstructured":"Endo I, Fukumoto S, Ozono K, Namba N, Inoue D, Okazaki R, Yamauchi M, Sugimoto T, Minagawa M, Michigami T, Nagai M, Matsumoto T et al (2015) Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J 62:811\u2013816","journal-title":"Endocr J"},{"key":"695_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1530\/EJE-15-0515","volume":"174","author":"S Rafaelsen","year":"2016","unstructured":"Rafaelsen S, Johansson S, R\u00e6der H, Bjerknes R (2016) Hereditary hypophosphatemia in Norway: a retrospective population- based study of genotypes, phenotypes, and treatment complications. Eur J Endocrinol 174:125\u2013136","journal-title":"Eur J Endocrinol"},{"key":"695_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00774-011-0340-2","volume":"30","author":"TO Carpenter","year":"2012","unstructured":"Carpenter TO (2012) The expanding family of hypophosphatemic syndromes. J Bone Miner Metab 30:1\u20139","journal-title":"J Bone Miner Metab"},{"key":"695_CR20","doi-asserted-by":"publisher","first-page":"F783","DOI":"10.1152\/ajprenal.00304.2010","volume":"300","author":"V David","year":"2011","unstructured":"David V, Martin A, Hedge AM, Drezner MK, Rowe PS (2011) ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate. Am J Physiol Renal Physiol 300:F783\u2013F791","journal-title":"Am J Physiol Renal Physiol"},{"key":"695_CR21","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s10545-018-0147-6","volume":"41","author":"D Chesher","year":"2018","unstructured":"Chesher D, Oddy M, Darbar U, Sayal P, Casey A, Ryan A, Sechi A, Simister C, Waters A, Wedatilake Y, Lachmann RH, Murphy E (2018) Outcome of adult patients with X- linked hypophosphatemia caused by PHEX gene mutations. J Inherit Metab Dis 41:865\u2013976","journal-title":"J Inherit Metab Dis"},{"key":"695_CR22","first-page":"4075","volume":"81","author":"MP Whyte","year":"1996","unstructured":"Whyte MP, Schranck FW, Armamento-Villareal R (1996) X- Linked hypophosphatemia: a search for gender, race, anticipation, or parent of origin effects on disease expression in children. J Clin Endocrinol Metab 81:4075\u20134080","journal-title":"J Clin Endocrinol Metab"},{"key":"695_CR23","doi-asserted-by":"publisher","first-page":"E38","DOI":"10.1152\/ajpendo.00008.2006","volume":"291","author":"S Liu","year":"2006","unstructured":"Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD (2006) Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 291:E38\u2013E49","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"695_CR24","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/jbmr.1766","volume":"28","author":"NM Barros","year":"2013","unstructured":"Barros NM, Hoac B, Neves RL, Addison WN, Assis DM, Murshed M, Carmona AK, McKee MD (2013) Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia. J Bone Min Res 28:688\u2013699","journal-title":"J Bone Min Res"},{"key":"695_CR25","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1210\/jc.2009-1671","volume":"95","author":"EA Imel","year":"2010","unstructured":"Imel EA, DiMeglio LA, Hui SL, Carpenter TO, Econs MJ (2010) Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab 95:1846\u20131850","journal-title":"J Clin Endocrinol Metab"},{"key":"695_CR26","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1172\/JCI81928","volume":"126","author":"X Bai","year":"2016","unstructured":"Bai X, Miao D, Xiao S, Qiu D, St-Arnaud R, Petkovich M, Gupta A, Goltzman D, Karaplis AC (2016) CYP24 inhibition as a therapeutic target in FGF23-mediated renal phosphate wasting disorders. J Clin Invest 126:667\u2013680","journal-title":"J Clin Invest"},{"key":"695_CR27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s00223-010-9373-0","volume":"87","author":"SS Beck-Nielsen","year":"2010","unstructured":"Beck-Nielsen SS, Brusgaard K, Rasmussen LM, Brixen K, Brock-Jacobsen B, Poulsen MR, Vestergaard P, Ralston SH, Albagha OM, Poulsen S, Haubek D, Gj\u00f8rup H, Hintze H, Andersen MG, Heickendorff L, Hjelmborg J, Gram J (2010) Phenotype presentation of hypophosphatemic rickets in adults. Calcif Tissue Int 87:108\u2013119","journal-title":"Calcif Tissue Int"},{"key":"695_CR28","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1530\/EJE-15-0661","volume":"174","author":"H Che","year":"2016","unstructured":"Che H, Roux C, Etcheto A, Rothenbuhler A, Kamenicky P, Linglart A, Briot K (2016) Impaired quality of life in adults with X- linked hypophosphatemia and skeletal symptoms. Eur J Endocrinol 174:325\u2013333","journal-title":"Eur J Endocrinol"},{"key":"695_CR29","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/0022034516677528","volume":"96","author":"M Biosse Duplan","year":"2017","unstructured":"Biosse Duplan M, Coyac BR, Bardet C, Zadikian C, Rothenbuhler A, Kamenicky P, Briot K, Linglart A, Chaussain C (2017) Phosphate and vitamin D prevent periodontitis in X- linked hypophosphatemia. J Dent Res 96:388\u2013395","journal-title":"J Dent Res"},{"key":"695_CR30","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1056\/NEJM199112263252604","volume":"325","author":"CF Verge","year":"1991","unstructured":"Verge CF, Lam A, Simpson JM, Cowell CT, Howard NJ, Silink M (1991) Effects of therapy in X- linked hypophosphatemic rickets. N Engl J Med 325:1843\u20131848","journal-title":"N Engl J Med"},{"key":"695_CR31","first-page":"33","volume":"45","author":"M Berndt","year":"1996","unstructured":"Berndt M, Ehrich JH, Lazovic D, Zimmermann J, Hillmann G, Kayser C, Prokop M, Schirg E, Siegert B, Wolff G, Brodehl J (1996) Clinical course of hypophosphatemic rickets in 23 adults. Clin Nephrol 45:33\u201341","journal-title":"Clin Nephrol"},{"key":"695_CR32","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/EC-13-0103","volume":"3","author":"A Linglart","year":"2014","unstructured":"Linglart A, Biosse-Duplan M, Briot K, Chaussain C, Esterle L, Guillaume-Czitrom S, Kamenicky P, Nevoux J, Pri\u00e9 D, Rothenbuhler A, Wicart P, Harvengt P (2014) Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect 3:R13\u2013R30","journal-title":"Endocr Connect"},{"key":"695_CR33","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"TO Carpenter","year":"2011","unstructured":"Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL (2011) A clinician\u2019s guide to X- linked hypophosphatemia. J Bone Miner Res 26:1381\u20131388","journal-title":"J Bone Miner Res"},{"issue":"1","key":"695_CR34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","volume":"14","author":"SS Beck-Nielsen","year":"2019","unstructured":"Beck-Nielsen SS, Mughal Z, Haffner D, Nilsson O, Levtchenko E, Ariceta G, de Lucas CC, Schnabel D, Jandhyala R, M\u00e4kitie O (2019) FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis 14(1):58","journal-title":"Orphanet J Rare Dis"},{"key":"695_CR35","doi-asserted-by":"publisher","first-page":"e1002427","DOI":"10.1371\/journal.pbio.1002427","volume":"14","author":"SK Murali","year":"2016","unstructured":"Murali SK, Andrukhova O, Clinkenbeard EL, White KE, Erben RG (2016) Excessive osteocytic Fgf23 secretion contributes to pyrophosphate accumulation and mineralization defect in Hyp Mice. PLoS Biol 14:e1002427","journal-title":"PLoS Biol"},{"issue":"4 Pt 1","key":"695_CR36","first-page":"E700","volume":"275","author":"ZS Xiao","year":"1998","unstructured":"Xiao ZS, Crenshaw M, Guo R, Nesbitt T, Drezner MK, Quarles LD (1998) Intrinsic mineralization defect in Hyp mouse osteoblasts. Am J Physiol 275(4 Pt 1):E700\u2013E708","journal-title":"Am J Physiol"},{"key":"695_CR37","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1172\/JCI81928","volume":"126","author":"X Bai","year":"2016","unstructured":"Bai X, Miao D, Xiao S, Qiu D, St-Arnaud R, Petkovich M et al (2016) CYP24 inhibition as a therapeutic target in FGF23-mediated renal phosphate wasting disorders. J Clin Invest 126:667\u2013680","journal-title":"J Clin Invest"},{"key":"695_CR38","doi-asserted-by":"publisher","first-page":"15872","DOI":"10.1074\/jbc.M701116200","volume":"282","author":"WN Addison","year":"2007","unstructured":"Addison WN, Azari F, Sorensen ES, Kaartinen MT, McKee MD (2007) Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up- regulating osteopontin, and inhibiting alkaline phosphatase activity. J Biol Chem 282:15872\u201315883","journal-title":"J Biol Chem"},{"key":"695_CR39","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/jbmr.110","volume":"25","author":"WN Addison","year":"2010","unstructured":"Addison WN, Masica DL, Gray JJ, McKee MD (2010) Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage. J Bone Min Res 25:695\u2013705","journal-title":"J Bone Min Res"},{"key":"695_CR40","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1530\/JOE-12-0143","volume":"214","author":"KA Staines","year":"2012","unstructured":"Staines KA, MacRae VE, Farquharson C (2012) The importance of the SIBLING family of proteins on skeletal mineralisation and bone remodelling. J Endocrinol 214:241\u2013255","journal-title":"J Endocrinol"},{"key":"695_CR41","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/jbmr.2079","volume":"29","author":"Q Yuan","year":"2014","unstructured":"Yuan Q, Jiang Y, Zhao X, Sato T, Densmore M, Sch\u00fcler C et al (2014) Increased osteopontin contributes to inhibition of bone mineralization in FGF23- deficient mice. J Bone Miner Res Off J Am Soc Bone Miner Res 29:693\u2013704","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"695_CR42","first-page":"229","volume":"33","author":"O Andrukhova","year":"2014","unstructured":"Andrukhova O, Smorodchenko A, Egerbacher M, Streicher C, Zeitz U, Goetz R et al (2014) FGF23 promotes renal calcium reabsorption through the TRPV5 channel. EMBO J 33:229\u2013246","journal-title":"EMBO J"},{"key":"695_CR43","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1359\/jbmr.090509","volume":"24","author":"Y Aono","year":"2009","unstructured":"Aono Y, Yamazaki Y, Yasutake J, Kawata T, Hasegawa H, Urakawa I et al (2009) Therapeutic effects of Anti-FGF23 antibodies in hypophosphatemic rickets\/ osteomalacia. J Bone Miner Res 24:1879\u20131888","journal-title":"J Bone Miner Res"},{"key":"695_CR44","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s00467-016-3505-3","volume":"32","author":"D Haffner","year":"2017","unstructured":"Haffner D, Leifheit-Nestler M (2017) Extrarenal effects of FGF23. Pediatr Nephrol 32:753\u2013765","journal-title":"Pediatr Nephrol"},{"key":"695_CR45","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.bbrc.2016.01.086","volume":"470","author":"C Sato","year":"2016","unstructured":"Sato C, Iso Y, Mizukami T, Otabe K, Sasai M, Kurata M et al (2016) Fibroblast growth factor-23 induces cellular senescence in human mesenchymal stem cells from skeletal muscle. Biochem Biophys Res Commun 470:657\u2013662","journal-title":"Biochem Biophys Res Commun"},{"key":"695_CR46","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1210\/JC.2015-2199","volume":"100","author":"J Connor","year":"2015","unstructured":"Connor J, Olear EA, Insogna KL, Katz L, Baker S, Kaur R et al (2015) Conventional therapy in adults With X-Linked hypophosphatemia: effects on enthesopathy and dental disease. J Clin Endocrinol Metab 100:3625\u20133632","journal-title":"J Clin Endocrinol Metab"},{"key":"695_CR47","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00590-014-1496-y","volume":"25","author":"V Pavone","year":"2015","unstructured":"Pavone V, Testa G, Gioitta Iachino S, Evola FR, Avondo S, Sessav G (2015) Hypophosphatemic rickets: etiology, clinical features and treatment. Eur J Orthop Surg Traumatol 25:221\u2013226","journal-title":"Eur J Orthop Surg Traumatol"},{"key":"695_CR48","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1210\/jc.2014-2017","volume":"99","author":"TO Carpenter","year":"2014","unstructured":"Carpenter TO, Olear EA, Zhang JH, Ellis BK, Simpson CA, Cheng D, Gundberg CM, Insogna KL (2014) Effect of paricalcitol on circulating parathyroid hormone in X- linked hypophosphatemia: a randomized, double- blind, placebo- controlled study. J Clin Endocrinol Metab 99:3103\u20133111","journal-title":"J Clin Endocrinol Metab"},{"key":"695_CR49","first-page":"4003","volume":"117","author":"IZ Ben-Dov","year":"2007","unstructured":"Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al (2007) The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117:4003\u20134008","journal-title":"J Clin Invest"},{"key":"695_CR50","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00223-017-0333-9","volume":"102","author":"ML Mace","year":"2018","unstructured":"Mace ML, Gravesen E, Nordholm A, Olgaard K, Lewin E (2018) Fibroblast growth factor (FGF) 23 regulates the plasma levels of parathyroid hormone in vivo through the FGF receptor in normocalcemia, but not in hypocalcemia. Calcif Tissue Int 102:85\u201392","journal-title":"Calcif Tissue Int"},{"key":"695_CR51","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1210\/jc.2002-021105","volume":"87","author":"Y Yamazaki","year":"2002","unstructured":"Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S (2002) Increased circulatory level of biologically active full- length FGF-23 in patients with hypophosphatemic rickets\/osteomalacia. J Clin Endocrinol Metab 87:4957\u20134960","journal-title":"J Clin Endocrinol Metab"},{"key":"695_CR52","doi-asserted-by":"publisher","first-page":"E352","DOI":"10.1210\/jc.2010-0589","volume":"95","author":"TO Carpenter","year":"2010","unstructured":"Carpenter TO, Insogna KL, Zhang JH, Ellis B, Nieman S, Simpson C, Olear E, Gundberg CM (2010) Circulating levels of soluble klotho and FGF23 in X- linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. J Clin Endocrinol Metab 95:E352\u2013E357","journal-title":"J Clin Endocrinol Metab"},{"key":"695_CR53","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, Wicart P, Bockenhauer D, Santos F, Levtchenko E, Harvengt P, Kirchhoff M, Di Rocco F, Chaussain C, Brandi ML, Savendahl L, Briot K, Kamenicky P, Rejnmark L, Linglart A (2019) Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 15:435\u2013455","journal-title":"Nat Rev Nephrol"},{"key":"695_CR54","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00467-002-1044-6","volume":"18","author":"US Alon","year":"2003","unstructured":"Alon US, Monzavi R, Lilien M, Rasoulpour M, Geffner ME, Yadin O (2003) Hypertension in hypophosphatemic rickets\u2014role of secondary hyperparathyroidism. Pediatr Nephrol 18:155\u2013158","journal-title":"Pediatr Nephrol"},{"key":"695_CR55","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1507\/endocrj.EJ16-0199","volume":"64","author":"Y Nakamura","year":"2017","unstructured":"Nakamura Y, Takagi M, Takeda R, Miyai K, Hasegawa Y (2017) Hypertension is a characteristic complication of X- linked hypophosphatemia. Endocr J 64:283\u2013289","journal-title":"Endocr J"},{"key":"695_CR56","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00467-004-1443-y","volume":"19","author":"CP Schmitt","year":"2004","unstructured":"Schmitt CP, Mehls O (2004) The enigma of hyperparathyroidism in hypophosphatemic rickets. Pediatr Nephrol 19:473\u2013477","journal-title":"Pediatr Nephrol"},{"key":"695_CR57","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1210\/jcem.82.2.3765","volume":"82","author":"MJ Econs","year":"1997","unstructured":"Econs MJ, McEnery PT (1997) Autosomal dominant hypophosphatemic rickets\/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 82:674\u2013681","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"695_CR58","doi-asserted-by":"crossref","first-page":"e10190","DOI":"10.1002\/jbm4.10190","volume":"13","author":"EA Imel","year":"2019","unstructured":"Imel EA, Biggin A, Schindeler A, Munns CF (2019) FGF23, Hypophosphatemia, and Emerging Treatments. JBMR Plus 13(3):e10190","journal-title":"JBMR Plus"},{"key":"695_CR59","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1210\/jc.2011-1239","volume":"96","author":"EA Imel","year":"2011","unstructured":"Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ (2011) Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab 96:3541\u20133549","journal-title":"J Clin Endocrinol Metab"},{"key":"695_CR60","doi-asserted-by":"publisher","first-page":"9843","DOI":"10.1074\/jbc.M210490200","volume":"278","author":"XY Bai","year":"2003","unstructured":"Bai XY, Miao D, Goltzman D, Karaplis AC (2003) The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 278:9843\u20139849","journal-title":"J Biol Chem"},{"key":"695_CR61","doi-asserted-by":"publisher","first-page":"120","DOI":"10.4248\/BR201302002","volume":"28","author":"X Huang","year":"2013","unstructured":"Huang X, Jiang Y, Xia W (2013) FGF23 and phosphate wasting disorders. Bone 28:120\u2013132","journal-title":"Bone"},{"key":"695_CR62","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ajhg.2010.01.010","volume":"86","author":"V Levy-Litan","year":"2010","unstructured":"Levy-Litan V, Hershkovitz E, Avizov L, Leventhal N, Bercovich D, Chalifa-Caspi V, Manor E, Buriakovsky S, Hadad Y, Goding J, Parvari R (2010) Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet 86:273\u2013278","journal-title":"Am J Hum Genet"},{"key":"695_CR63","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/ng1221","volume":"34","author":"F Rutsch","year":"2003","unstructured":"Rutsch F, Ruf N, Vaingankar S, Toliat MR, Suk A, H\u00f6hne W, Schauer G, Lehmann M, Roscioli T, Schnabel D, Epplen JT, Knisely A, Superti-Furga A, McGill J, Filippone M, Sinaiko AR, Vallance H, Hinrichs B, Smith W, Ferre M, Terkeltaub R, N\u00fcrnberg P (2003) Mutations in ENPP1 are associated with \u2018idiopathic\u2019 infantile arterial calcification. Nat Genet 34:379\u2013381","journal-title":"Nat Genet"},{"key":"695_CR64","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00467-009-1273-z","volume":"25","author":"J Gattineni","year":"2010","unstructured":"Gattineni J, Baum M (2010) Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism. Pediatr Nephrol 25:591\u2013601","journal-title":"Pediatr Nephrol"},{"key":"695_CR65","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00431-010-1382-5","volume":"170","author":"US Alon","year":"2011","unstructured":"Alon US (2011) Clinical practice. Fibroblast growth factor (FGF)23: a new hormone. Eur J Pediatr 170:545\u2013554","journal-title":"Eur J Pediatr"},{"key":"695_CR66","doi-asserted-by":"publisher","first-page":"F371","DOI":"10.1152\/ajprenal.00090.2008","volume":"295","author":"G Jaureguiberry","year":"2008","unstructured":"Jaureguiberry G, Carpenter TO, Forman S, Harald J\u00fcppner H, Bergwitz C (2008) A novel missense mutation in SLC34A3 that causes hereditary hypophosphatemic rickets with hypercalciuria in humans identifies threonine 137 as an important determinant of sodium-phosphate cotransport in NaPi-IIc. Am J Physiol Renal Physiol 295:F371\u2013F379","journal-title":"Am J Physiol Renal Physiol"},{"key":"695_CR67","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1086\/499410","volume":"78","author":"B Lorenz-Depiereux","year":"2006","unstructured":"Lorenz-Depiereux B, Benet-Pages A, Eckstein G, Tenenbaum-Rakover Y, Wagenstaller J, Tiosano D, Gershoni-Baruch R, Albers N, Lichtner P, Schnabel D, Hochberg Z, Strom TM (2006) Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. Am J Hum Genet 78:193\u2013201","journal-title":"Am J Hum Genet"},{"key":"695_CR68","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00424-018-2184-2","volume":"471","author":"C Bergwitz","year":"2019","unstructured":"Bergwitz C, Miyamoto KI (2019) Hereditary hypophosphatemic rickets with hypercalciuria: pathophysiology, clinical presentation, diagnosis and therapy. Pflugers Arch 471:149\u2013163","journal-title":"Pflugers Arch"},{"key":"695_CR69","doi-asserted-by":"publisher","first-page":"C1316","DOI":"10.1152\/ajpcell.00314.2011","volume":"302","author":"S Haito-Sugino","year":"2012","unstructured":"Haito-Sugino S, Ito M, Ohi A, Shiozaki Y, Kangawa N, Nishiyama T, Aranami F, Sasaki S, Mori A, Kido S, Tatsumi S, Segawa H, Miyamoto KI (2012) Processing and stability of type IIc sodium-dependent phosphate cotransporter mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria. Am J Physiol Cell Physiol 302:C1316\u2013C1330","journal-title":"Am J Physiol Cell Physiol"},{"key":"695_CR70","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1750-1172-5-28","volume":"5","author":"O Devuyst","year":"2010","unstructured":"Devuyst O, Thakker RV (2010) Dent\u2019s disease. Orphanet J Rare 5:28","journal-title":"Orphanet J Rare"},{"key":"695_CR71","first-page":"473","volume":"87","author":"OM Wrong","year":"1994","unstructured":"Wrong OM, Norden AG, Feest TG (1994) Dent\u2019s disease; a familial proximal renal tubular syndrome with low-molecular- weight proteinuria, hypercalciuria, nephrocalcinosis, metabolic bone disease, progressive renal failure and a marked male predominance. QJM 87:473\u2013493","journal-title":"QJM"},{"issue":"105","key":"695_CR72","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1073\/pnas.0712361105","volume":"4","author":"CA Brownstein","year":"2008","unstructured":"Brownstein CA, Adler F, Nelson-Williams C, Iijima J, Li P, Imura A, Nabeshima Y, Reyes-Mugica M, Carpenter TO, Lifton RP (2008) A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci U S A 4(105):3455\u20133460","journal-title":"Proc Natl Acad Sci U S A"},{"key":"695_CR73","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ecl.2010.02.004","volume":"39","author":"PJ Malloy","year":"2010","unstructured":"Malloy PJ, Feldman D (2010) Genetic disorders and defects in vitamin D action. Endocrinol Metab Clin N Am 39:333\u2013346","journal-title":"Endocrinol Metab Clin N Am"},{"key":"695_CR74","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/MED.0b013e32835a3415","volume":"19","author":"D Tiosano","year":"2012","unstructured":"Tiosano D, Gepstein V (2012) Vitamin D action: lessons learned from hereditary 1,25-dihydroxyvitamin-D-resistant rickets patients. Curr Opin Endocrinol Diabetes Obes 19:452\u2013459","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"2","key":"695_CR75","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bonr.2015.05.001","volume":"7","author":"T Isojima","year":"2015","unstructured":"Isojima T, Ishizawa M, Yoshimura K, Tamura M, Hirose S, Makishima M, Kitanaka S (2015) Hereditary 1,25-dihydroxyvitamin D-resistant rickets (HVDRR) caused by a VDR mutation: a novel mechanism of dominant inheritance. Bone Rep 7(2):68\u201373","journal-title":"Bone Rep"},{"key":"695_CR76","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJM199803053381004","volume":"338","author":"S Kitanaka","year":"1998","unstructured":"Kitanaka S, Takeyama K, Murayama A, Sato T, Okumura K, Nogami M, Hasegawa Y, Niimi H, Yanagisawa J, Tanaka T, Kato S (1998) Inactivating mutations in the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in patients with pseudovitamin D-deficiency rickets. N Engl J Med 338:653\u2013661","journal-title":"N Engl J Med"},{"key":"695_CR77","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s11914-015-0259-y","volume":"13","author":"BK Goldsweig","year":"2015","unstructured":"Goldsweig BK, Carpenter TO (2015) Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis. Curr Osteoporos Rep 13:88\u201397","journal-title":"Curr Osteoporos Rep"},{"key":"695_CR78","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s00774-009-0079-1","volume":"27","author":"D Tiosano","year":"2009","unstructured":"Tiosano D, Hochberg Z (2009) Hypophosphatemia: the common denominator of all rickets. J Bone Miner Metab 27:392\u2013401","journal-title":"J Bone Miner Metab"},{"key":"695_CR79","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.bone.2008.02.014","volume":"42","author":"I Endo","year":"2008","unstructured":"Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsumoto T (2008) Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemicpatients: proposal of diagnostic criteria using FGF23 measurement. Bone 42:1235\u20131239","journal-title":"Bone"},{"key":"695_CR80","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1507\/endocrj.K10E-257","volume":"58","author":"JM Igaki","year":"2011","unstructured":"Igaki JM, Yamada M, Yamazaki Y, Koto S, Izawa M, Ariyasu D, Suzuki E, Hasegawa H, Hasegawa Y (2011) High iFGF23 level despite hypophosphatemia is one of the clinical indicators to make diagnosis of XLH. Endocr J 58:647\u2013655","journal-title":"Endocr J"},{"key":"695_CR81","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00223-017-0307-y","volume":"101","author":"JCD SouberbiellePrie\u0301","year":"2017","unstructured":"SouberbiellePrie\u0301 JCD, Piketty ML, Rothenbuhler A, Delanaye P, Chanson P, Cavalier E (2017) Evaluation of a new fully automated assay for plasma intact FGF23. Calcif Tissue Int 101:510\u2013518","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"695_CR82","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40272-020-00381-8","volume":"22","author":"V Saraff","year":"2020","unstructured":"Saraff V, Nadar R, H\u00f6gler W (2020) New developments in the treatment of X-linked hypophosphataemia: implications for clinical management. Paediatr Drugs. 22(2):113\u2013121","journal-title":"Paediatr Drugs."},{"key":"695_CR83","doi-asserted-by":"publisher","first-page":"154049","DOI":"10.1016\/j.metabol.2019.154049","volume":"103S","author":"AL Lecoq","year":"2020","unstructured":"Lecoq AL, Brandi ML, Linglart A, Kamenick\u00fd P (2020) Management of X-linked hypophosphatemia in adults. Metabolism 103S:154049","journal-title":"Metabolism"},{"key":"695_CR84","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1359\/jbmr.080417","volume":"23","author":"Y Yamazaki","year":"2008","unstructured":"Yamazaki Y, Tamada T, Kasai N, Urakawa I, Aono Y, Hasegawa H et al (2008) Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res Off J Am Soc Bone Miner Res 23:1509\u20131518","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"695_CR85","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","volume":"7","author":"MP Whyte","year":"2019","unstructured":"Whyte MP, Carpenter TO, Gottesman GS et al (2019) Efficacy and safety of burosumab in children aged 1\u20134 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol 7:189\u2013199","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"21","key":"695_CR86","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","volume":"378","author":"TO Carpenter","year":"2018","unstructured":"Carpenter TO, Whyte MP, Imel EA et al (2018) Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med 378(21):1987\u20131998","journal-title":"N Engl J Med"},{"key":"695_CR87","unstructured":"US Food & Drug Administration. CRYSVITA (prescribing information) (2018) FDA.gov"},{"key":"695_CR88","unstructured":"European Medicines Agency. Crysvita. Annex I \u2014 summary of product characteristics. EMA (2018)"},{"issue":"393","key":"695_CR89","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","volume":"15","author":"EA Imel","year":"2019","unstructured":"Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, H\u00f6gler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Mao M, Chen CY, Skrinar A, San Martin J, Portale AA (2019) Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 15(393):2416\u20132427","journal-title":"Lancet"},{"issue":"3","key":"695_CR90","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","volume":"105","author":"AA Portale","year":"2019","unstructured":"Portale AA, Carpenter TO, Brandi ML, Briot K, Cheong HI, Cohen-Solal M, Crowley R, Jan De Beur S, Eastell R, Imanishi Y, Imel EA, Ing S, Ito N, Javaid M, Kamenicky P, Keen R, Kubota T, Lachmann R, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Zhang L, Theodore-Oklota C, Mealiffe M, San Martin J, Insogna K (2019) Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period. Calcif Tissue Int 105(3):271\u2013284","journal-title":"Calcif Tissue Int"},{"key":"695_CR91","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jbspin.2019.01.012","volume":"86","author":"AS Lambert","year":"2019","unstructured":"Lambert AS, Zhukouskaya V, Rothenbuhler A, Linglart A (2019) X-linked hypophosphatemia: Management and treatment prospects. Joint Bone Spine 86:731\u2013738","journal-title":"Joint Bone Spine"},{"key":"695_CR92","doi-asserted-by":"publisher","first-page":"E1146","DOI":"10.1073\/pnas.1110905108","volume":"108","author":"EG Farrow","year":"2011","unstructured":"Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, Stayrook KR, Jideonwo V, Magers MJ, Garringer HJ, Vidal R, Chan RJ, Goodwin CB, Hui SL, Peacock M, White KE (2011) Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A 108:E1146\u2013E1155","journal-title":"Proc Natl Acad Sci U S A"},{"key":"695_CR93","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/jbmr.3336","volume":"33","author":"EA Imel","year":"2018","unstructured":"Imel EA, Liu Z, Coffman M, Acton D, Econs MJ (2018) Oral Iron Therapy Normalizes Fibroblast Growth Factor 23 (FGF23) in Patients with Autosomal Dominant Hypophosphatemic Rickets. J Bone Miner Res 33:S1\u2013S56","journal-title":"J Bone Miner Res"},{"key":"695_CR94","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJM198503073121003","volume":"312","author":"M Tieder","year":"1985","unstructured":"Tieder M, Modai D, Samuel R, Arie R, Halabe A, Bab I, Gabizon D, Liberman UA (1985) Hereditary hypophosphatemic rickets with hypercalciuria. N Engl J Med 312:611\u2013617","journal-title":"N Engl J Med"},{"key":"695_CR95","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJM198701153160302","volume":"316","author":"M Tieder","year":"1987","unstructured":"Tieder M, Modai D, Shaked U, Samuel R, Arie R, Halabe A, Maor J, Weissgarten J, Averbukh Z, Cohen N et al (1987) \u201cIdiopathic\u201d hypercalciuria and hereditary hypophosphatemic rickets. Two phenotypical expressions of a common genetic defect. N Engl J Med 316:125\u2013129","journal-title":"N Engl J Med"},{"key":"695_CR96","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.berh.2003.09.004","volume":"17","author":"AJ Reginato","year":"2003","unstructured":"Reginato AJ, Coquia JA (2003) Musculoskeletalmanifestations of osteomalacia and rickets. Best Pract Res Clin Rheumatol 17:1063\u20131080","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"695_CR97","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1055\/s-2008-1076716","volume":"117","author":"B Kremke","year":"2009","unstructured":"Kremke B, Bergwitz C, Ahrens W, Schutt S, Schumacher M, Wagner V, Holterhus PM, J\u00fcppner H, Hiort O (2009) Hypophosphatemic rickets with hypercalciuria due to mutation in SLC34A3\/NaPi-IIc can be masked by vitamin D deficiency and can be associated with renal calcifications. Exp Clin Endocrinol Diabetes 117:49\u201356","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"695_CR98","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/ng1095-130","volume":"11","author":"HYP-Consortium","year":"1995","unstructured":"HYP-Consortium (1995) A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11:130\u2013136","journal-title":"Nat Genet"},{"key":"695_CR99","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/81664","volume":"26","author":"ADHR Consortium","year":"2000","unstructured":"ADHR Consortium (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345\u2013348","journal-title":"Nat Genet"},{"key":"695_CR100","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1056\/NEJMoa0802836","volume":"359","author":"Z Karim","year":"2008","unstructured":"Karim Z, Gerard B, Bakouh N, Alili R, Leroy C, Beck L, Silve C, Planelles G, Urena-Torres P, Grandchamp B, Friedlander G, Prie D (2008) NHERF1 mutations and responsiveness of renal parathyroid hormone. N Engl J Med 359:1128\u20131135","journal-title":"N Engl J Med"},{"key":"695_CR101","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1056\/NEJMoa020028","volume":"347","author":"D Prie","year":"2002","unstructured":"Prie D, Huart V, Bakouh N, Planelles G, Dellis O, Gerard B, Hulin P, Benque-Blanchet F, Silve C, Grandchamp B, Friedlander G (2002) Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodiumphosphate cotransporter. N Engl J Med 347:983\u2013991","journal-title":"N Engl J Med"},{"key":"695_CR102","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.pcl.2018.09.003","volume":"66","author":"AM Ehlayel","year":"2019","unstructured":"Ehlayel AM, Copelovitch L (2019) Update on Dent Disease. Pediatr Clin North Am 66:169\u2013178","journal-title":"Pediatr Clin North Am"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-020-00695-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-020-00695-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-020-00695-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T02:27:30Z","timestamp":1696127250000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-020-00695-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,14]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["695"],"URL":"https:\/\/doi.org\/10.1007\/s00223-020-00695-2","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,14]]},"assertion":[{"value":"20 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GM declares that she has no conflict of interests. MLB has received honoraria from Amgen, Bruno Farmaceutici, Calcilytix, Kyowa Kirin; academic grants from and\/or was speaker for Abiogen, Alexion, Amgen, Bruno Farmaceutici, Eli Lilly, Kyowa Kirin, MSD, NPS, Servier, Shire, SPA; and has been consultant for Alexion, Bruno Farmaceutici, Kyowa Kirin, Servier, Shire.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}